A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition

Conditions

• X-Linked Myotubular Myopathy

Eligibility Criteria

Sex

MALE

Age

N/A - 17 Years

Healthy Volunteers

Not accepted

Interventions

• No Intervention — OTHER
  No investigational drug will be administered to participants in this study.

Study Details

XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition. Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM. There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study. This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas). In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study. This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.

Key Dates

Start date

May 19, 2025

Status verified

May 2026

Primary completion

May 31, 2027

Completion

May 31, 2027

Study Design

Enrollment

50 participants (estimated)

Arms

• Arm: Participants with XLMTM
  Pediatric and adolescent participants with XLMTM.

Primary Outcome Measure

Incidence rate of cholestasis [ Time Frame: Up to Week 48 ]

Central Contacts

• Astellas Gene Therapies
  800-888-7704
  [email protected]

Locations (6)

Find similar trials in Chicago, IL

Related Studies

• Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
  PHASE1/PHASE2 · Recruiting · Astellas Gene Therapies · Chicago, Illinois